needed effects
ombitasvir
paritaprevir
ritonavir
unwanted side effects
medical attention
paritaprevir
ritonavir side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
common side effects
patients with genotype hepatitis c virus
hcv
infection
drug in combination with dasabuvir
ribavirin
fatigue
nausea
common side effects
patients with genotype hcv infection
drug with ribavirin
asthenia
fatigue
nausea
insomnia
common side effect
such patients
drug without ribavirin
asthenia
manufacturer product information for dasabuvir
ribavirin
asthenia
fatigue
nausea
insomnia
pruritus
combination therapy with dasabuvir
ribavirin
combination therapy with dasabuvir
ribavirin
most skin reactions
mild severity
pruritus
pruritus
generalized pruritus
skin reactions
rash
erythema
eczema
maculopapular rash
macular rash
dermatitis
papular rash
skin exfoliation
pruritic rash
erythematous rash
generalized rash
allergic dermatitis
contact dermatitis
exfoliative rash
photosensitivity reaction
psoriasis
skin reaction
ulcer
urticaria
elevated alt
elevated total bilirubin
hyperbilirubinemiapostmarketing reports
hepatic decompensation
hepatic failure
combination therapy with dasabuvir
ribavirin for weeks
alt
times
upper limit of normal
uln
alt
uln
total bilirubin
uln
total bilirubin
uln
patients
combination therapy with dasabuvir
ribavirin
weeks
alt
uln
total bilirubin
uln
patients
combination therapy with dasabuvir
ribavirin
weeks
alt
uln
alt
uln
total bilirubin
uln
cirrhosis patients
clinical trials with this drug
dasabuvir
ribavirin
patients
post-baseline serum alt levels
uln during therapy
incidence
women
using
product
containing ethinyl estradiol
increase in incidence of alt elevations
estrogens
ethinyl estradiol
estradiol
conjugated estrogens
alt elevations
first weeks of therapy
days
range
days
continued use
elevated alt
elevated bilirubin
cirrhosis
risk factor for elevated alt
transient serum bilirubin elevations
patients
using combination therapy with dasabuvir
ribavirin
increases
inhibition of oatpb/b
bilirubin transporters
paritaprevir
ribavirin-induced hemolysis
bilirubin elevations
therapy initiation
week of the study
ongoing therapy
elevated bilirubin
aminotransferase elevations
transient elevations in total bilirubin
uln
hcv/hiv
coinfected patients
using combination therapy with dasabuvir
ribavirin
patients
using atazanavir
concurrent elevations of aminotransferases
hyperbilirubinemia
none of the patients
genotype hcv
post-baseline alt levels
uln
starting
drug
post-baseline bilirubin elevations
uln
hcv genotype
infected patients
drug with ribavirin
increases
inhibition of oatpb/b
bilirubin transporters
paritaprevir
ribavirin-induced hemolysis
bilirubin elevations
start of therapy
week of the study
ongoing therapy
elevated bilirubin
elevated serum alt
hepatic decompensation
hepatic failure
including liver transplantation
fatal outcomes
patients
paritaprevir
ritonavir
dasabuvir
ribavirin
most patients with these severe outcomes
evidence of advanced cirrhosis
starting therapy
cases
weeks
starting therapy
acute onset
rising
rising direct serum bilirubin levels without increases in alt
clinical signs/symptoms of hepatic decompensation
anemia
hemoglobin
hgb
combination therapy with dasabuvir
ribavirin for weeks
hgb
g/dl
hgb
g/dl
patients
combination therapy with dasabuvir
ribavirin
weeks
hgb
g/dl
hgb
g/dl
hgb
g/dl
cirrhosis patients
least post-baseline hgb value
g/dl
post-liver transplant patients
using combination therapy with dasabuvir
ribavirin
ribavirin dose
patients
decreased hgb
ribavirin
patient
patients
ribavirin
starting dose
mg/day
erythropoietin
patient
blood transfusion
change from baseline in hgb levels
g/dl in patients
drug with ribavirin
g/dl in patients
drug
hgb level
therapy
week
further decreases through week
low hgb values
therapy
baseline levels by weeks after therapy
least patient
drug with ribavirin
single hgb level decrease
g/dl during therapy
ribavirin dose
anemia/decreased hgb levels
patient
blood transfusion
erythropoietin
patients
drug
hgb levels
g/dl
postmarketing reports
hypersensitivity reactions
including angioedema
side effects of technivie
fda
healthcare professional for medical advice
stomach pain
chills
clay-colored stools
dark urine
dizziness
fever
headache
itching or rash
loss of appetite
nausea
unpleasant breath odor
unusual tiredness
weakness
vomiting of blood
yellow eyes
skin
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
blistering
crusting
irritation
itching
reddening of the skin
scaly skin
increased sensitivity of the skin
sunlight
lack
loss of strength
redness
other discoloration of the skin
severe sunburn
skin rash
oozing
swelling
trouble sleeping